Hamilton, Stanley R.

Tumor Microsatellite-Instability Status as a Predictor of Benefit from Fluorouracil-Based Adjuvant Chemotherapy for Colon Cancer

Ribic, C. M., Sargent, D. J., Moore, M. J., Thibodeau, S. N., French, A. J., Goldberg, R. M., Hamilton, S. R., Laurent-Puig, P., Gryfe, R., Shepherd, L. E., et al. (2003) · New England Journal of Medicine

Genetic factors in colorectal cancerColorectal Cancer Treatments and Studies

Cited by 2,160

Defective Mismatch Repair As a Predictive Marker for Lack of Efficacy of Fluorouracil-Based Adjuvant Therapy in Colon Cancer

Sargent, D. J., Marsoni, S., Monges, G., Thibodeau, S. N., Labianca, R., Hamilton, S. R., French, A. J., Kabat, B., Foster, N. R., Torri, V., et al. (2010) · Journal of Clinical Oncology

Genetic factors in colorectal cancerColorectal Cancer Treatments and Studies

Cited by 1,623

Methylation of the oestrogen receptor CpG island links ageing and neoplasia in human colon

Issa, J.-P. J., Ottaviano, Y. L., Celano, P., Hamilton, S. R., Davidson, N. E., & Baylin, S. B. (1994) · Nature Genetics

Epigenetics and DNA MethylationGenetic factors in colorectal cancer

Cited by 1,191

American Society of Clinical Oncology Provisional Clinical Opinion: Testing for KRAS Gene Mutations in Patients With Metastatic Colorectal Carcinoma to Predict Response to Anti–Epidermal Growth Factor Receptor Monoclonal Antibody Therapy

Allegra, C. J., Jessup, J. M., Somerfield, M. R., Hamilton, S. R., Hammond, E. H., Hayes, D. F., McAllister, P. K., Morton, R. F., & Schilsky, R. L. (2009) · Journal of Clinical Oncology

Colorectal Cancer Treatments and StudiesLung Cancer Treatments and Mutations

Cited by 1,156

Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH)

Flaherty, K. T., Gray, R. J., Chen, A. P., Li, S., McShane, L. M., Patton, D., Hamilton, S. R., Williams, P. M., Iafrate, A. J., Sklar, J., et al. (2020) · Journal of Clinical Oncology

Cancer Genomics and DiagnosticsLung Cancer Treatments and Mutations

Cited by 294

Intraoperative Determination of Small Intestinal Viability following Ischemic Injury: A Prospective, Controlled Trial of Two Adjuvant Methods (Doppler and Fluorescein) Compared with Standard Clinical Judgment

BULKLEY, G. B., ZUIDEMA, G. D., HAMILTON, S. R., OʼMARA, C. S., KLACSMANN, P. G., & HORN, S. D. (1981) · Annals of Surgery

Abdominal vascular conditions and treatmentsIntestinal and Peritoneal Adhesions

Cited by 203

Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q

Jhaveri, K. L., Wang, X. V., Makker, V., Luoh, S.-W., Mitchell, E. P., Zwiebel, J. A., Sharon, E., Gray, R. J., Li, S., McShane, L. M., et al. (2019) · Annals of Oncology

HER2/EGFR in Cancer ResearchLung Cancer Treatments and Mutations

Cited by 151

Acquired resistance to KRAS G12C small-molecule inhibitors via genetic/nongenetic mechanisms in lung cancer

Mohanty, A., Nam, A., Srivastava, S., Jones, J., Lomenick, B., Singhal, S. S., Guo, L., Cho, H., Li, A., Behal, A., et al. (2023) · Science Advances

Lung Cancer Treatments and MutationsProtein Kinase Regulation and GTPase Signaling

Cited by 79

Clinical and Molecular Features of KRAS-Mutated Lung Cancer Patients Treated with Immune Checkpoint Inhibitors

Zhao, D., Li, H., Mambetsariev, I., Mirzapoiazova, T., Chen, C., Fricke, J., Kulkarni, P., Villaflor, V., Arvanitis, L., Hamilton, S., et al. (2022) · Cancers

Lung Cancer Treatments and MutationsCancer Immunotherapy and Biomarkers

Cited by 24